BioCentury
ARTICLE | Financial News

July 2 Financial Quick Takes: Suspension continues for Woodford fund; plus CRUK, Codiak and Amarin

July 2, 2019 9:22 PM UTC

Woodford extends fund suspension
Woodford Investment Management Ltd. extended to July 29 the suspension of trading in its flagship fund, Woodford Equity Income Fund. The extension’s purpose is to allow the fund manager more time to reposition the fund's portfolio into more liquid, publicly traded holdings. Trading was initially suspended on June 3 due to concerns that the fund couldn't meet a growing demand for redemptions. Since the suspension, the share price of another publicly traded Woodford fund, Woodford Patient Capital Trust (LSE:WPCT), has fallen 27% to 55.1p (see "Woodford Suspends Trade in Flagship Fund").

CRUK teams with SV Health Investors, contributes to fund
Cancer Research UK is investing $25 million in SV Health Investors' planned $250 million, biotech-only, seventh fund as part of a new partnership. The oncology research charity will collaborate with the firm to identify opportunities in CRUK's network that are ripe for investment. SV intends to invest about 60% of the fund in cancer companies...